Mesa Laboratories (NASDAQ:MLAB) Announces Earnings Results

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) posted its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.78 by ($0.25), Zacks reports. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The firm had revenue of $63.72 million for the quarter, compared to analysts' expectations of $65.21 million. During the same period in the prior year, the firm earned ($1.31) earnings per share.

Mesa Laboratories Stock Down 1.3%

Mesa Laboratories stock opened at $104.08 on Tuesday. Mesa Laboratories has a twelve month low of $55.45 and a twelve month high of $113.99. The firm has a 50 day moving average price of $101.71 and a 200-day moving average price of $90.40. The company has a market capitalization of $574.52 million, a P/E ratio of 86.73 and a beta of 0.94. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Friday, May 29th were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 29th. Mesa Laboratories's dividend payout ratio is currently 53.33%.

Hedge Funds Weigh In On Mesa Laboratories

Institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its position in shares of Mesa Laboratories by 1.2% during the 1st quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier's stock valued at $3,652,000 after purchasing an additional 353 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Mesa Laboratories in the first quarter worth about $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Mesa Laboratories by 4.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock valued at $364,000 after purchasing an additional 143 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Mesa Laboratories by 3.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier's stock valued at $2,370,000 after buying an additional 685 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier's stock worth $1,265,000 after acquiring an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Mesa Laboratories from a "sell (d+)" rating to a "sell (d)" rating in a research report on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Reduce" and an average target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.